BTEC:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 6.775

Change

-0.20 (-2.89)%

Market Cap

N/A

Volume

0.14M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 544.83B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 544.83B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 209.75B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B
0R24:LSE Intel Corp.

N/A

USD 196.14B

ETFs Containing BTEC:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.19% 71% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.19% 70% C- 65% D
Trailing 12 Months  
Capital Gain 14.76% 79% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.76% 78% C+ 73% C
Trailing 5 Years  
Capital Gain 44.47% 68% D+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.47% 65% D 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 5.76% 55% F 60% D-
Dividend Return 5.76% 54% F 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.05% 36% F 51% F
Risk Adjusted Return 30.22% 49% F 62% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.